The Study
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
This study watched what happened to people who took a medicine called semaglutide and noticed they lost weight and felt better. But it didn't compare them to people who didn't take it, so we can't be sure the medicine was the reason they improved.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Doctors gave a medicine called semaglutide to obese people to help them lose weight and improve their health.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 545 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Losing 10% or more of your body weight can significantly lower your risk of heart disease and diabetes — this study shows many people achieved that with one shot a week.
- 2On average, people lost 13.4% of their body weight.
- 3Non-diabetic people lost 16.9%, while diabetic people lost 9.9%.
- 464% lost at least 10% of their weight, and 22% lost 20% or more.
- 5Their blood pressure, cholesterol, and liver health also improved.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
International Journal of Obesity
Year
2024
Authors
W. Ghusn, S. Fansa, D. Añazco, Elif Tama, Bryan Nicolalde, Khushboo S Gala, Alan De la Rosa, D. Sacoto, Lizeth Cifuentes, Alejandro Campos, Fauzi Feres, M. Hurtado, Andres Acosta
Related Content
Claims (6)
In people who are overweight or obese but do not have diabetes, the medication semaglutide lowers the risk of serious heart-related events such as heart attack or stroke, and this benefit occurs even when some of the effect is not due to weight loss.
In adults with obesity taking semaglutide for 12 months, measurable improvements were seen in blood sugar, cholesterol, blood pressure, liver enzymes, and cardiovascular risk indicators.
In a group of adults with obesity who were given the medication semaglutide, 64% lost at least 10% of their body weight and 41% lost at least 15% after one year of treatment.
In adults with obesity who took weekly semaglutide for one year, most lost at least 5% of their body weight, with many losing 10% or more, and a smaller group losing 20% or more.
Among adults with obesity taking semaglutide for a year, those without type 2 diabetes lost an average of 16.9% of their body weight, while those with type 2 diabetes lost an average of 9.9%.
Among adults with obesity who were prescribed semaglutide in a real-world setting, most were women and White, which means the results from this group may not apply equally to men or people from other racial backgrounds.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.